Immune Mediated Cerebellar Ataxia: An Unknown Manifestation of Graft-versus-Host Disease

Acta Haematol. 2019;141(1):19-22. doi: 10.1159/000494423. Epub 2018 Nov 15.

Abstract

Neurologic complications of allogeneic hematopoietic cell transplantation (allo-HCT) include infections, cerebrovascular events, therapy-induced neurotoxicity, recurrent malignancies, and neurologic manifestations of graft-versus-host disease (GVHD). Anti-glutamic acid decarboxylase (GAD) antibody-associated cerebellar ataxia is a well-established disorder of autoimmune origin, but there are no reports in the literature of its occurrence following allo-HCT. We describe a middle-aged woman with chronic GVHD after allo-HCT who presented with a rapidly progressive cerebellar syndrome. Thorough investigation revealed only cerebellar atrophy on brain imaging and positive anti-GAD65 antibodies in serum and cerebrospinal fluid suggesting the diagnosis of anti-GAD antibody-associated cerebellar ataxia. Despite prompt treatment with high-dose corticosteroids, intravenous immunoglobulins, and rituximab, the patient's condition rapidly deteriorated, and she died 4 months later. This case suggests that anti-GAD antibody-associated cerebellar ataxia may be a rare manifestation of chronic GVHD.

Keywords: Allogeneic transplant; Anti-GAD antibody; Cerebellar ataxia; Graft-versus-host disease.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / therapeutic use
  • Autoantibodies / blood
  • Cerebellar Ataxia / complications
  • Cerebellar Ataxia / diagnosis*
  • Cerebellar Ataxia / drug therapy
  • Female
  • Graft vs Host Disease / diagnosis*
  • Graft vs Host Disease / etiology
  • Hematopoietic Stem Cell Transplantation / adverse effects
  • Humans
  • Immunoglobulins, Intravenous
  • Leukemia, Myeloid / therapy
  • Middle Aged
  • Rituximab / therapeutic use
  • Transplantation, Homologous / adverse effects

Substances

  • Antineoplastic Agents, Immunological
  • Autoantibodies
  • Immunoglobulins, Intravenous
  • Rituximab